Literature DB >> 33965452

Inhibition of c-MET reverses radiation-induced malignant potential in pancreatic cancer.

Soichiro Mori1, Hirofumi Akita2, Shogo Kobayashi3, Yoshifumi Iwagami4, Daisaku Yamada4, Yoshito Tomimaru4, Takehiro Noda4, Kunihito Gotoh4, Yutaka Takeda5, Masahiro Tanemura6, Yuichiro Doki4, Hidetoshi Eguchi4.   

Abstract

As a treatment option for PDAC, radiation therapy induces good local control. However, radiation also reportedly enhances the malignant potential (e.g., invasion and migration ability) in various cancers, thus increasing the risk of distant metastasis. It remains unclear how radiation induces malignant potential, and how such enhanced malignant potential can be suppressed. In the current study, we evaluated the sequential change of c-Met expression in pancreatic cancer cells following irradiation. We found that irradiation transiently induced c-Met expression in vitro. In an in vivo subcutaneous tumor mouse model, irradiation also enhanced downstream phosphorylated Met (p-Met). Furthermore, this enhancement of p-Met protein expression was suppressed by oral administration of the c-Met inhibitor INC280. Irradiated pancreatic cancer cells with enhanced c-Met expression exhibited higher malignant potential, including invasion and migration ability, compared with cells showing low c-Met expression. Pancreatic cancer cells that overexpressed c-met also showed enhanced malignant potential, which was reversed by c-Met inhibition. Additionally, c-Met inhibitor suppressed the metastatic potential in a liver metastasis mouse model using c-met-overexpressing cells. Overall, our present results revealed that irradiation could induce c-met expression in pancreatic cancer cells, leading to enhanced malignant potential (e.g., invasion and migration ability) and thus promoting distant metastasis. Moreover, a c-Met inhibitor could reverse this enhanced malignant potential.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  INC280; Metastasis; Phosphorylated-met; c-Met inhibitor

Year:  2021        PMID: 33965452     DOI: 10.1016/j.canlet.2021.04.029

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  4 in total

1.  Impact of pathological complete response following neoadjuvant chemotherapy (gemcitabine, nab-paclitaxel, S-1) and radiation for borderline resectable pancreatic cancer: a case report and review of literature.

Authors:  Mitsuru Kinoshita; Sota Watanabe; Gaku Mizojiri; Akitada Sada; Hiroki Kai; Yasunori Masuike; Yoshinobu Nagasawa; Kentaro Maruyama; Kyowon Lee; Mai Ohata; Osamu Ishikawa; Hiroshi Oka
Journal:  Surg Case Rep       Date:  2022-09-14

2.  The Relationship between MACC1/c-Met/Cyclin D1 Axis Expression and Prognosis in ESCC.

Authors:  Yan Shi; Meng-Yan Li; Hui Wang; Chao Li; Wen-Ying Liu; Yong-Mei Gao; Bo Wang; Jia-Wei Song; Yu-Qing Ma
Journal:  Anal Cell Pathol (Amst)       Date:  2022-02-22       Impact factor: 2.916

Review 3.  Opportunities and challenges of targeting c-Met in the treatment of digestive tumors.

Authors:  Zhengchao Zhang; Dong Li; Heng Yun; Jie Tong; Wei Liu; Keqiang Chai; Tongwei Zeng; Zhenghua Gao; Yongqiang Xie
Journal:  Front Oncol       Date:  2022-08-01       Impact factor: 5.738

Review 4.  Impact of One-Carbon Metabolism-Driving Epitranscriptome as a Therapeutic Target for Gastrointestinal Cancer.

Authors:  Yu Takeda; Ryota Chijimatsu; Andrea Vecchione; Takahiro Arai; Toru Kitagawa; Ken Ofusa; Masami Yabumoto; Takaaki Hirotsu; Hidetoshi Eguchi; Yuichiro Doki; Hideshi Ishii
Journal:  Int J Mol Sci       Date:  2021-07-06       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.